RAD101 PET met its Phase 2b endpoint in brain metastases, but $4M cash against $13M quarterly burn means Phase 3 lives or dies on imminent financing

Radiopharm Theranostics is a clinical-stage company developing RAD101, a PET imaging agent for detecting recurrent brain metastases, which is not yet approved.

RAD101, a PET imaging agent for suspected recurrent brain metastases, met its Phase 2b primary endpoint with 93% concordance against MRI, and a Siemens Healthineers manufacturing partnership is in place for Phase 3. Whether this becomes a registrational program depends on two inseparable conditions: FDA alignment on pivotal trial design at the October meeting and concurrent resolution of a near-fatal financing gap. With $4M cash against $13.2M quarterly burn, the company cannot reach a Phase 3 readout without repeated dilutive raises, each of which the market has already penalized.